1. Get the Diabetes Forum App for your phone - available on iOS and Android.
    Dismiss Notice
  2. Guest, we'd love to know what you think about the forum! Take the Diabetes Forum Survey 2022 »
    Dismiss Notice
  3. Diabetes Forum should not be used in an emergency and does not replace your healthcare professional relationship. Posts can be seen by the public.
    Dismiss Notice
Dismiss Notice
Find support, ask questions and share your experiences. Join the community »

Forxiga fast-tracked in US to help prevent heart attacks

Discussion in 'Diabetes News' started by DCUK NewsBot, Sep 16, 2019.

  1. DCUK NewsBot

    DCUK NewsBot · Well-Known Member

    Likes Received:
    Trophy Points:
    A diabetes drug has been fast-tracked through official channels so it can be made immediately available in the US to help reduce deadly heart attacks. The US Food and Drug Administration (FDA) has given official approval for dapagliflozin, which is marketed as Forxiga and Farxiga, and produced by pharmaceutical company AstraZeneca, to be accessible for people with heart failure. The FDA has a thorough process it must follow before new drugs can come to market, which can sometimes be cumbersome. However, the organisation will fast-track new treatments for serious conditions where there is an unmet need. Forxiga is an SGLT2 inhibitor drug that works by allowing the kidneys to release more glucose through the urine. It is usually given to people with type 2 diabetes. The FDA grant came after AstraZeneca reported positive results in a trial of patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). They reported that Forxiga had reduced both cardiovascular death and worsening of heart failure in this trial. Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: "Heart failure affects approximately 64 million people worldwide, and about half will die within five years of diagnosis. "This Fast Track designation for Farxiga brings us closer to fulfilling our ambition to help prevent, treat and cure heart failure, and we look forward to working with the FDA to explore Farxiga as a potential new treatment option for heart failure patients." Farxiga is a first-in-class, oral once-daily SGLT2 inhibitor given to people with type 2 diabetes to improve their glycaemic control. It is recommended the drug is taken in addition with exercise and healthy eating, which will help with weight loss and blood pressure reduction. In the UK, the drug was recently recommended by the National Institute for Health and Care Excellence (NICE) for use in type 1 diabetes. However, the FDA has rejected it for use in type 1 diabetes in the US. The drug has been involved in 35 clinical trials so far, with some studies continuing to test its potential for use in other health conditions.

    Continue reading...
  • Meet the Community

    Find support, connect with others, ask questions and share your experiences with people with diabetes, their carers and family.

    Did you know: 7 out of 10 people improve their understanding of diabetes within 6 months of being a Diabetes Forum member. Get the Diabetes Forum App and stay connected on iOS and Android

    Grab the app!
  • Tweet with us

  • Like us on Facebook